- Clinically-Documented Benefits
- 25+ Years of Research and Clinical Studies For Vaginal and Urinary Tract Health
- More Than 20 Studies Demonstrating Safety and Efficacy
- Patented Lactobacilli Strains: GR-1® and RC-14®
- Prevention Magazine: Top 10 Breakthrough ’07
GR-1®/RC-14® and Vaginal FLORA (also called microbiota) In one of the randomized clinical trials, 75% of women in the GR-1®/RC-14® probiotic group experienced significant improvement in vaginal flora composition, while only 34% of women in the placebo (non-probiotic) group experienced similar improvement. Fem-Dophilus® contains two patented and clinically documented probiotic strains, Lacticaseibacillus rhamnosus GR-1®‡ and Limosilactobacillus reuteri RC-14®‡, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 25 years of research supports the oral use of GR-1® and RC-14® to colonize and promote healthy vaginal and urinary tract health. A special manufacturing process protects the probiotic strains in Fem-Dophilus® from stomach acid and enhances probiotic bacterial survival to the lower intestine. ‡Updates based on official taxonomy reclassification. **25+ Years of GR-1®/RC-14® research/clinical studies.
For maintenance, take 1 capsule orally per day, preferably with a meal and a glass of water, and increase to 2 capsules per day as needed or take as directed by your qualified healthcare professional. If your healthcare professional recommends taking this product in conjunction with antibiotics, take at least 1-2 hours after taking the medication.
Keep refrigerated. Keep out of the reach of children. Consult a healthcare professional before using this product if you are trying to conceive, pregnant, or lactating, under the age of 18, or have a medical condition; if adverse reactions occur, discontinue use.
결제 및 보안
지불 정보가 안전하게 처리됩니다. 저희는 신용 카드 정보를 저장하지 않으며 신용 카드 정보에 대한 액세스 권한을 가지고 있지 않습니다.